SPPI Spectrum Pharmaceuticals Inc

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) securities between May 7, 2015 and October 23, 2015.

Click here to learn about the case: http://docs.wongesq.com/SPPI-Info-Request-Form-1012. There is no cost or obligation to you.

The complaint alleges that Spectrum Pharmaceuticals violated federal securities laws by disseminating materially false and misleading information and failing to disclose material facts, causing the stock to trade at artificially inflated prices.

On October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. Upon this news, shares of Spectrum Pharmaceuticals fell more than 20% on intraday trading.

If you suffered a loss in Spectrum Pharmaceuticals you have until January 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SPPI-Info-Request-Form-1012.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

 

CONTACT:    
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com